RESUMO
BACKGROUND: Betel quid chewing is more common among the older generation in rural areas of Malaysia. Oral cancer in Asia has been associated with the habit of chewing betel quid and areca nut. OBJECTIVE: This study aims to investigate the cytotoxic effects of betel quid and areca nut extracts on the fibroblast (L929), mouth-ordinary-epithelium 1 (MOE1) and oral squamous cell carcinoma (HSC-2) cell lines. METHODS: L929, MOE1 and HSC-2 cells were treated with 0.1, 0.2 and 0.4 g/ml of betel quid and areca nut extracts for 24, 48 and 72 h. MTT assay was performed to assess the cell viability. RESULTS: Both extracts, regardless of concentration, significantly reduced the cell viability of L929 compared with the control (P<0.05). Cell viability of MOE1 was significantly enhanced by all betel quid concentrations compared with the control (P<0.05). By contrast, 0.4 g/ml of areca nut extract significantly reduced the cell viability of MOE1 at 48 and 72 h of incubation. Cell viability of HSC-2 was significantly lowered by all areca nut extracts, but 0.4 g/ml of betel quid significantly increased the cell viability of HSC-2 (P<0.05). CONCLUSION: Areca nut extract is cytotoxic to L929 and HSC-2, whereas the lower concentrations of areca nut extract significantly increased the cell viability of MOE1 compared to the higher concentration and control group. Although betel quid extract is cytotoxic to L929, the same effect is not observed in MOE1 and HSC-2 cell lines. Further investigations are needed to clarify the mechanism of action.
.
Assuntos
Apoptose/efeitos dos fármacos , Areca/química , Carcinoma de Células Escamosas/patologia , Fibroblastos/efeitos dos fármacos , Neoplasias Bucais/patologia , Neoplasias Epiteliais e Glandulares/patologia , Extratos Vegetais/farmacologia , Animais , Areca/classificação , Carcinoma de Células Escamosas/tratamento farmacológico , Sobrevivência Celular , Células Cultivadas , Fibroblastos/patologia , Humanos , Camundongos , Neoplasias Bucais/tratamento farmacológico , Neoplasias Epiteliais e Glandulares/tratamento farmacológico , Nozes/químicaRESUMO
Helicobacter pylori (Hp) infection is related to the pathogenesis of chronic gastric disorders and extragastric diseases. Here, we examined the anorexigenic and anxiogenic effects of Hp vacuolating cytotoxin A (VacA) through activation of hypothalamic urocortin1 (Ucn1). VacA was detected in the hypothalamus after peripheral administration and increased Ucn1 mRNA expression and c-Fos-positive cells in the hypothalamus but not in the nucleus tractus solitarius. c-Fos and Ucn1-double positive cells were detected. CRF1 and CRF2 receptor antagonists suppressed VacA-induced anxiety and anorexia, respectively. VacA activated single paraventricular nucleus neurons and A7r5 cells; this activation was inhibited by phospholipase C (PLC) and protein kinase C (PKC) inhibitors. VacA causes anorexia and anxiety through the intracellular PLC-PKC pathway, migrates across the blood-brain barrier, and activates the Ucn1-CRF receptor axis.
Assuntos
Anorexia/induzido quimicamente , Ansiedade/induzido quimicamente , Citotoxinas/toxicidade , Helicobacter pylori/citologia , Hipotálamo/efeitos dos fármacos , Urocortinas/metabolismo , Vacúolos/metabolismo , Animais , Anorexia/genética , Ansiedade/genética , Peso Corporal/efeitos dos fármacos , Ingestão de Alimentos/efeitos dos fármacos , Gerbillinae , Helicobacter pylori/fisiologia , Hipotálamo/citologia , Hipotálamo/metabolismo , Camundongos , RNA Mensageiro/genética , Transdução de Sinais/efeitos dos fármacos , Urocortinas/genéticaRESUMO
About half of all cancer patients show a syndrome of cachexia, characterized by anorexia and loss of adipose tissue and skeletal muscle mass. Numerous cytokines have been postulated to play a role in the etiology of cancer cachexia. Cytokines can elicit effects that mimic leptin signaling and suppress orexigenic ghrelin and neuropeptide Y signaling, inducing sustained anorexia and cachexia not accompanied by the usual compensatory response. Furthermore, cytokines have been implicated in the induction of cancer-related muscle wasting. In particular, tumor necrosis factor-alpha, interleukin-1, interleukin-6 and interferon-gamma have been implicated in the induction of cancer-related muscle wasting. Cytokine-induced skeletal muscle wasting is probably a multifactorial process, which involves a depression in protein synthesis, an increase in protein degradation or a combination of both. Cancer patients suffer from the reduction in physical function, tolerance to anti-cancer therapy and survival, while many effective chemotherapeutic agents for cancer are burdened by toxicities that can reduce patient's quality of life or hinder their effective use. Herbal medicines have been widely used to help improve such conditions. Recent studies have shown that herbal medicines such as rikkunshito enhance ghrelin signaling and consequently improve nausea, appetite loss and cachexia associated with cancer or cancer chemotherapy, which worsens the quality of life and life expectancy of the patients. The multicomponent herbal medicines capable of targeting multiple sites could be useful for future drug discovery. Mechanistic studies and identification of active compounds could lead to new discoveries in biological and biomedical sciences.
Assuntos
Anorexia/induzido quimicamente , Antineoplásicos/efeitos adversos , Caquexia/fisiopatologia , Caquexia/terapia , Medicamentos de Ervas Chinesas/farmacologia , Neoplasias/tratamento farmacológico , Fitoterapia/métodos , Tecido Adiposo/patologia , Animais , Anorexia/complicações , Antineoplásicos/administração & dosagem , Caquexia/tratamento farmacológico , Caquexia/etiologia , Caquexia/metabolismo , Medicamentos de Ervas Chinesas/uso terapêutico , Grelina/efeitos dos fármacos , Grelina/metabolismo , Medicina Herbária , Humanos , Medicina Kampo , Músculo Esquelético/patologia , Neoplasias/complicações , Cuidados Paliativos/métodos , Desnutrição Proteico-Calórica/etiologia , Desnutrição Proteico-Calórica/fisiopatologia , Desnutrição Proteico-Calórica/terapia , Qualidade de Vida , Transdução de Sinais/efeitos dos fármacosRESUMO
Ghrelin is a growth hormone (GH) secretagogue and a potent orexigenic factor that stimulates feeding by interacting with hypothalamic feeding-regulatory nuclei. Its multifaceted effects are potentially beneficial as a treatment in human disease states. In both adult and pediatric chronic kidney disease (CKD) patients, decreased appetite plays a major role in wasting, which in turn is linked to morbidity and mortality; wasting has also been linked to high levels of leptin and proinflammatory cytokines. The beneficial effects of ghrelin treatment in CKD are potentially mediated by multiple concurrent actions, including the stimulation of appetite-regulating centers, anti-inflammatory effects, and direct kidney effects. Further evaluation of this appetite-regulating hormone in CKD is needed to confirm previous findings and to determine the underlying mechanisms.
Assuntos
Regulação do Apetite , Caquexia/etiologia , Grelina/metabolismo , Hipotálamo/metabolismo , Insuficiência Renal Crônica/complicações , Animais , Anti-Inflamatórios/uso terapêutico , Estimulantes do Apetite/uso terapêutico , Caquexia/tratamento farmacológico , Caquexia/metabolismo , Caquexia/fisiopatologia , Caquexia/psicologia , Citocinas/metabolismo , Grelina/uso terapêutico , Humanos , Hipotálamo/fisiopatologia , Mediadores da Inflamação/metabolismo , Insuficiência Renal Crônica/tratamento farmacológico , Insuficiência Renal Crônica/metabolismo , Insuficiência Renal Crônica/fisiopatologia , Insuficiência Renal Crônica/psicologia , Transdução de SinaisRESUMO
Kampo, a form of traditional herbal medical practice, has become a substance of interest for scientific research. Although earlier clinical reports concerning Kampo are abundant, the scientific investigation of Kampo has a very short history. However, the process of acquiring quantifiable clinical trial evidence on herbal medicine is now clearly underway. The development of multi-component herbal medicines capable of targeting multiple sites could be useful both for future drug discovery and for the potential management of complex diseases. Additionally, mechanistic studies and the identification of active compounds could lead to new discoveries in the biological and biomedical sciences. Modern translational research on herbal medicines beyond basic science and clinical perspectives will contribute to the development of new medicines. This review covers the translational aspects of herbal medicine with a focus on cancer anorexiacachexia. The review gives perspective on a new horizon for herbal medicine from a scientific point of view and a basis for the further development of complementary and alternative medicine (CAM) for patients.
Assuntos
Anti-Inflamatórios não Esteroides/uso terapêutico , Antineoplásicos Fitogênicos/uso terapêutico , Estimulantes do Apetite/uso terapêutico , Caquexia/tratamento farmacológico , Medicina Kampo , Preparações de Plantas/uso terapêutico , Pesquisa Translacional Biomédica/tendências , Animais , Anti-Inflamatórios não Esteroides/farmacologia , Antineoplásicos Fitogênicos/farmacologia , Estimulantes do Apetite/farmacologia , Caquexia/etiologia , Caquexia/imunologia , Caquexia/metabolismo , Grelina/agonistas , Grelina/metabolismo , Humanos , Hipotálamo/efeitos dos fármacos , Hipotálamo/imunologia , Hipotálamo/metabolismo , Neoplasias/tratamento farmacológico , Neoplasias/etiologia , Neoplasias/fisiopatologia , Neurônios/efeitos dos fármacos , Neurônios/imunologia , Neurônios/metabolismo , Preparações de Plantas/farmacologia , Receptores de Grelina/agonistas , Receptores de Grelina/metabolismo , Transdução de Sinais/efeitos dos fármacosRESUMO
Although the mechanism of action of acetaminophen (AAP) is not fully understood, some studies suggest that AAP and phenacetin (PHE) are selective cyclooxygenase (COX)-3 inhibitors. To examine the participation of COX-3 in memory formation, water maze performance was studied in mice treated with AAP, PHE or other COX inhibitors. Mice received intraperitoneal injections of drugs immediately after each training session. Administration of high-dose AAP [302.3 mg/kg (IC50 for COX-2)] or PHE [179.2 mg/kg (IC50 for COX-2)] and of non-specific (indomethacin: 20 mg/kg) or specific COX-2 (NS-398: 10 mg/kg) inhibitor impaired the performance in hidden platform (HP) not visible platform (VP) tasks, whereas low-dose (15.1 mg/kg) AAP facilitated performance in HP and VP tasks. The facilitation of performance by low-dose AAP was reversed by co-administration with a 5-HT(1/2) receptor antagonist (methysergide: 0.47 mg/kg). The middle-dose [69.5 mg/kg (IC50 for COX-3)] of AAP, the PHE [17.9 mg/kg (IC50 for COX-3)] and a specific COX-1 inhibitor (piroxicam: 10-20 mg/kg) did not influence performance in either task. These results suggest that the memory impairment by high-dose AAP and PHE and facilitation of performance by low-dose AAP could involve endogenous COX-2 and serotonergic neuronal activity, but not COX-3, respectively.